Pulmonary Hypertension Model Selection: PAH and CTEPH Research

​Among cardiopulmonary disorders in translational research, pulmonary hypertension remains one of the most complex. The disease includes multiple etiologies, overlapping mechanisms, and variable rates of progression. These factors create major challenges during preclinical drug development. A model that reflects vascular remodeling may fail to capture thrombosis. Another may reproduce hemodynamic dysfunction but not inflammatory signaling.

For sponsors developing therapies for pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), model selection directly affects translational relevance. The chosen platform must align with the mechanism of action (MoA), target biology, and intended clinical population. Careful selection also improves endpoint interpretation and reduces uncertainty before IND-enabling studies.

Understanding the Distinct Biology of Pulmonary Hypertension

PAH and CTEPH both involve elevated pulmonary vascular resistance and progressive right ventricular strain. However, the underlying biology differs substantially.

PAH is characterized by pulmonary arterial remodeling. Key features include endothelial dysfunction, smooth muscle proliferation, inflammation, fibrosis, and altered vasoactive signaling. In advanced disease, plexiform lesions and severe vascular narrowing contribute to right heart failure.

CTEPH develops through unresolved thromboembolic obstruction. Persistent clot burden triggers secondary vascular remodeling and chronic pressure overload. Small vessel disease may emerge over time, but thrombosis and impaired fibrinolysis remain central drivers.

These distinctions matter during model selection. A therapy targeting endothelial proliferation requires a different platform than a fibrinolytic or anticoagulant strategy. Researchers must determine whether the study should prioritize:

• Vascular remodeling

• Pulmonary hemodynamics

• Thrombotic burden

• Inflammation

• Right ventricular adaptation

• Fibrotic progression

No single model captures every component simultaneously.

Selecting Models for Pulmonary Vascular Remodeling

Several established in vivo models reproduce key aspects of PAH pathophysiology. Each provides advantages and limitations depending on the therapeutic hypothesis.

The monocrotaline rat model remains widely used for evaluating pulmonary vascular injury and right ventricular hypertrophy. Monocrotaline induces endothelial damage, inflammatory activation, and progressive pulmonary pressure elevation. The model is relatively reproducible and supports longitudinal hemodynamic assessment. However, the toxic injury mechanism differs from human PAH initiation. Moreover, the model is limited in duration by a high, non-CV mortality rate as of Day 28 or so.

The SU5416 plus hypoxia model generates more severe pulmonary vascular remodeling. VEGF receptor inhibition combined with chronic hypoxia produces occlusive lesions and marked right ventricular dysfunction. This model better reflects advanced proliferative disease. It is particularly useful for therapies targeting angiogenic signaling, smooth muscle proliferation, or vascular remodeling pathways. The model features low mortality and is often prolonged to 56, 63 days to take advantage of its ability to produce neo-intimal lesions resembling the plexiform lesions seen in human patients.

Chronic hypoxia exposure models pulmonary vasoconstriction and mild remodeling. These systems are valuable for studying hypoxia-responsive signaling and pulmonary pressure regulation. Structural pathology is generally less severe than in human PAH.

Modeling Hemodynamics and Right Ventricular Dysfunction

Pulmonary vascular pathology alone does not fully predict clinical outcomes. Right ventricular adaptation strongly influences morbidity and survival in pulmonary hypertension.

Hemodynamic characterization should therefore remain central during model planning. Key measurements often include:

• Right ventricular systolic pressure

• Mean pulmonary arterial pressure

• Pulmonary vascular resistance

• Cardiac output

• Right ventricular hypertrophy indices

Telemetry and catheter-based measurements improve temporal resolution and translational value. Echocardiography also supports non-invasive assessment of chamber structure and function.

Importantly, right ventricular failure does not develop uniformly across models. Some systems produce elevated pulmonary pressures without severe cardiac remodeling. Others generate maladaptive hypertrophy and ventricular fibrosis.

Choosing Translational Models for CTEPH Research

CTEPH modeling remains more challenging than PAH research. Human disease involves persistent thromboembolic obstruction combined with secondary microvascular remodeling. Replicating this multifactorial progression in animals is technically demanding.

Repeated embolization models are commonly used to induce chronic pulmonary vascular obstruction. Microspheres, blood clots, or synthetic particles create sustained pulmonary hypertension over time. These systems support investigation of thrombotic burden and hemodynamic consequences.

However, embolic persistence varies between species due to differences in fibrinolytic activity. Researchers often modify protocols to improve chronic obstruction and vascular remodeling.

Larger animal models may better support surgical and interventional studies relevant to pulmonary endarterectomy or balloon pulmonary angioplasty research. These platforms also facilitate advanced imaging and pressure monitoring.

For therapies targeting thrombosis or fibrinolysis, experimental design should incorporate coagulation biomarkers and clot-resolution endpoints. Relevant measures may include:

• Thrombus organization

• Vascular recanalization

• Inflammatory infiltration

• Pulmonary artery remodeling

• Exercise tolerance metrics

CTEPH studies often require extended timelines because chronic remodeling develops gradually after embolic injury.

Aligning Model Selection With Mechanism of Action

The strongest preclinical pulmonary hypertension programs begin with MoA-driven model selection. Investigators should define the dominant biological question before choosing a platform.

A therapy targeting endothelin signaling may require robust vasoconstrictive and remodeling components. Anti-inflammatory agents should demonstrate measurable immune activation within the selected model. Anti-fibrotic compounds require reproducible extracellular matrix deposition and tissue remodeling endpoints.

Combination strategies may require sequential or complementary models. Early screening may occur in rodent systems, followed by translational confirmation in large animals with advanced hemodynamic monitoring.

Building a More Translational Pulmonary Hypertension Program

Successful pulmonary hypertension research depends on selecting models that reproduce the biological mechanisms most relevant to the therapeutic strategy. No single platform captures every aspect of PAH or CTEPH. Translational strength comes from matching disease features, study endpoints, and pharmacologic intent.

IPS Therapeutique supports sponsors with tailored in vivo pulmonary hypertension studies designed to address efficacy, mechanism, and translational decision-making. If your team is evaluating therapies for PAH, CTEPH, or related cardiopulmonary disorders, send us a message today.